In today’s marketplace, manufacturers need more than just coverage data to improve patient access. Real-world data (RWD)—from sources like medical and pharmacy claims, lab tests and results, and EHRs—reveals how patients actually received care.
That’s where we come in. In a first-of-its-kind offering, MMIT integrates all of these RWD sources with payer coverage and clinical pathways data, creating a unified record of the patient journey. We take the burden of analysis off your shoulders, delivering dashboards of bridged data to answer your critical questions.
Resolve Access Barriers Throughout
the Patient Journey
Our integrated data dashboards let you track a patient cohort from diagnosis to treatment, noting the critical events and triggers along the way—from test results to payer restrictions that impact provider behavior.
Science to Symptoms
Diagnosis to Prescription
Treatment to End of Therapy
from 2017 onwards, representing commercial, Medicaid & Medicare populations.
View 6+ years of longitudinal data with annual addition of 200m+ patients/year.
with more than 6.5m+ affiliations.
Gain insight into 7K+ hospitals, 5,600+ health systems, and 1,500+ ACOs.
with benefit plan details like PA, step therapy and quantity limit restrictions.
See rebates, coupons, deductibles, co-insurance and full payment amounts.
covering 210m+ U.S. lives, with 500m+ diagnostic test results/month.
Track 177m+ lab patients with linked claims and view 200m+ test results from inpatient hospitals.
How many patients are actively being managed for their disease?
What are lengths of therapy?
What HCPs are managing patients and what influences treatment decision?
How can I identify and stratify patients with the condition my therapy treats?
What tests are being done at the HCP and institution level to identify patients with the condition?
How can I target HCPs after they order a test and before they diagnose and prescribe?
How are payers making coverage decisions for my brand?
What hurdles exist at the plan level for patients to be prescribed?
Even though my therapy is preferred by a payer, is my competitor’s therapy getting more utilization at that payer?
What are the critical pathways at the institution level and how are they driving treatment decisions?
Where are the advantages/ disadvantages to payer coverage?
Patients who have been diagnosed with ovarian, fallopian tube or primary peritoneal cancer over a given time period.
Patients who have successfully completed a frontline platinum-based regimen.
Patients who are in remission and haven’t moved on to a second therapy.
Patients in remission who are actively being managed and maintain levels through lab testing (Cancer Antigen / CA 125).
Eligible patients at Texas Oncology.
Patient Access Analytics
This solution combines coverage, claims and pathways data to provide commercial pharma teams with a unique view of payer and prescriber behavior.
Lab Data for Commercial Targeting
MMIT’s Lab Data assets and analysis help manufacturers target the right providers and patients at the right time, before a diagnosis or prescribing decision is made.
Our RWD powered solutions use mastered, linked and tokenized data assets to deliver clear insights across the patient journey.